Vantage Investor Diligence · Sample Report
A next-generation abdominal aortic aneurysm (AAA) endograft with active supra-renal fixation, evaluated at Series A. A stand-in target, weighed against real, verifiable comparables.
Meridian is attacking the one failure mode that has repeatedly killed AAA-endograft companies: Type III endoleak and device migration in the years after implant. Its active-fixation design is a credible answer to a real, cohort-documented problem — but the company sits pre-pivotal, and the endovascular graveyard is full of technically elegant devices that never proved durable seal at scale. The cohort below is unusually instructive: four of Meridian's five closest comparables reached acquisition, and the one that failed did so on precisely the risk Meridian's technology targets.
What actually happened to endovascular device companies at or beyond Meridian's stage. Every identifier is a link to the primary public record — click any of them.
| Company | What it is | Public record | Outcome |
|---|---|---|---|
| Endologix, Inc. | AAA endograft (AFX platform) — the closest comparable | K120212,
K111747,
K110090 (FDA 510k) |
Chapter 11 · 2020 |
| Vascular Solutions | Peripheral & coronary vascular devices | 73 FDA records · NASDAQ: VASC | Acquired · Teleflex 2017 (~$1B) |
| Shockwave Medical | Intravascular lithotripsy for calcified disease | 31 registered trials · NASDAQ: SWAV | Acquired · J&J 2024 ($13.1B) |
| Inari Medical | Mechanical venous thrombectomy (FlowTriever) | 9 registered trials · NASDAQ: NARI | Acquired · Stryker 2025 ($4.9B) |
| Penumbra, Inc. | Computer-assisted vacuum thrombectomy | 86 FDA 510(k) records · NYSE: PEN | Acquired · Boston Scientific 2026 |
Sources: openFDA 510(k) database, SEC EDGAR, and the acquirers' own completion announcements. Every figure above is a real public record.
Four of the five closest comparables reached acquisition; the one that failed — Endologix — collapsed on exactly the failure mode Meridian's active-fixation design targets: Type III endoleak and graft migration surfacing years after implant, culminating in recalls and a 2020 Chapter 11. The cohort's dividing line is not the idea — it's the durability evidence. The companies that exited carried multi-year post-implant seal data and a reimbursement path that leaned on existing AAA-repair coding, not a new code. Meridian's Series A is fundable if it buys exactly that: a fixation-durability dataset before the pivotal, not after.
IDE → PMA is the right, expected pathway for a new AAA endograft. Bench durability and a clean first-in-human are the gating reads before a pivotal is financeable.
Active supra-renal fixation is mechanically credible against the migration failure mode. Freedom-to-operate around existing fixation and sealing-ring claims is the load-bearing IP question.
Strongest when it maps to existing EVAR MS-DRG / CPT coding rather than requiring a new code — the lesson the exited comparables share and the failed one did not solve.
Pre-pivotal capital intensity is the central risk: endograft pivotals are long and expensive. Runway to a durability readout — not to the pivotal — is the milestone that de-risks the round.
We'll run the same read — real comparables, cited to public record — on a company you're weighing, and walk you through it. Your materials stay confidential; that's the point.
Methodology. Meridian Endovascular is a stand-in company created to show the Vantage diligence framework in full without exposing a client's confidential work; none of its specifics represent a real entity, and it carries no fabricated regulatory identifiers. Every comparable company is real and every hard fact about them is cited to public record — openFDA · ClinicalTrials.gov · SEC EDGAR — and independently verifiable via the links above. Domain indices are shown with illustrative credible intervals. The Vantage Index is a defined composite statistic, characteristic of the evidence available — not a prediction of outcome.